CN115175696A - 包含白喉毒素交叉反应物质（crm）氨基酸序列的蛋白颗粒及其用途 - Google Patents

包含白喉毒素交叉反应物质（crm）氨基酸序列的蛋白颗粒及其用途 Download PDF

Info

Publication number
CN115175696A
CN115175696A CN202080080056.6A CN202080080056A CN115175696A CN 115175696 A CN115175696 A CN 115175696A CN 202080080056 A CN202080080056 A CN 202080080056A CN 115175696 A CN115175696 A CN 115175696A
Authority
CN
China
Prior art keywords
protein
amino acid
acid sequence
composition
crm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080080056.6A
Other languages
English (en)
Chinese (zh)
Inventor
B·H·A·雷姆
S·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffith University
Original Assignee
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Griffith University filed Critical Griffith University
Publication of CN115175696A publication Critical patent/CN115175696A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080080056.6A 2019-09-20 2020-09-21 包含白喉毒素交叉反应物质（crm）氨基酸序列的蛋白颗粒及其用途 Pending CN115175696A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2023863A NL2023863B1 (en) 2019-09-20 2019-09-20 Protein particles and uses thereof
NL2023863 2019-09-20
PCT/AU2020/000107 WO2021051153A1 (en) 2019-09-20 2020-09-21 Protein particles comprising a diphtheria toxin cross reacting material (crm) amino acid sequence and uses thereof

Publications (1)

Publication Number Publication Date
CN115175696A true CN115175696A (zh) 2022-10-11

Family

ID=68425230

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080080056.6A Pending CN115175696A (zh) 2019-09-20 2020-09-21 包含白喉毒素交叉反应物质（crm）氨基酸序列的蛋白颗粒及其用途

Country Status (7)

Country Link
US (1) US20220378894A1 (https=)
EP (1) EP4031170A4 (https=)
JP (1) JP2022549791A (https=)
CN (1) CN115175696A (https=)
AU (1) AU2020349589A1 (https=)
NL (1) NL2023863B1 (https=)
WO (1) WO2021051153A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116286682A (zh) * 2022-12-30 2023-06-23 中国农业科学院兰州兽医研究所 O型口蹄疫病毒多表位仿生纳米自组装病毒样颗粒及其制备方法和应用
CN117723749A (zh) * 2024-02-07 2024-03-19 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
CN118191298A (zh) * 2022-12-14 2024-06-14 上海索昕生物科技有限公司 一种抗体免疫检测试剂及其制备方法和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109078177B (zh) * 2018-08-09 2022-07-08 安徽智飞龙科马生物制药有限公司 一种预防结核病的疫苗及联合用药物和制备方法、应用
CA3218711A1 (en) * 2021-05-13 2022-11-17 Roee Amit Methods and compositions for treatment of viral infection
CN113801209B (zh) * 2021-11-16 2022-02-11 浙江普康生物技术股份有限公司 一种具有广谱中和活性的新型冠状病毒重组蛋白及其制备方法
CN114835822B (zh) * 2022-04-22 2022-11-04 浙江洪晟生物科技股份有限公司 猪瘟病毒的多聚体疫苗及其制备方法
WO2025106425A1 (en) * 2023-11-13 2025-05-22 University Of Florida Research Foundation, Incorporated Immunogenic composition and uses thereof
CN119552230B (zh) * 2024-12-12 2026-03-13 中国人民解放军军事科学院军事医学研究院 一种脂肪酸化修饰的白喉毒素抗原及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100999548A (zh) * 2006-01-10 2007-07-18 海南天源康泽医药科技有限公司 白喉毒素突变体crm197及其制备方法
CN108159408A (zh) * 2017-12-29 2018-06-15 云南沃森生物技术股份有限公司 一种多价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用
CN109963586A (zh) * 2016-07-21 2019-07-02 维克芙奥私人有限公司 作为抗疟疾疫苗的生物融合蛋白

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514506A (en) 1982-02-23 1985-04-30 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
US5047238A (en) 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
PL196114B1 (pl) * 2002-12-31 2007-12-31 Inst Biotechnologii I Antybiot Ciałka inkluzyjne jako antygeny do doustnej immunizacji zwierząt
CN102686238A (zh) * 2009-09-09 2012-09-19 马特里瓦克斯研究和开发公司 具有改善的免疫原性的蛋白质基质疫苗
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
KR20130072201A (ko) * 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
IN2012MU00206A (https=) * 2012-01-20 2013-08-09
WO2015134402A1 (en) * 2014-03-03 2015-09-11 Scarab Genomics, Llc Enhanced production of recombinant crm197 in e. coli
KR102730367B1 (ko) 2014-04-15 2024-11-15 그리피스 유니버시티 그룹 a 스트렙토코쿠스 백신
WO2016172762A1 (en) 2015-04-25 2016-11-03 James Cook University Schistosomiasis vaccine
GB201509782D0 (en) 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
GB201706430D0 (en) 2017-04-24 2017-06-07 Univ Oxford Innovation Ltd Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof
KR102893870B1 (ko) 2017-08-23 2025-12-02 그리피스 유니버시티 그룹 a 스트렙토코쿠스에 대한 면역원성 펩티드
EP3706787A4 (en) * 2017-11-06 2021-10-20 OZQ Pty Ltd VACCINE
US12053519B2 (en) * 2018-09-23 2024-08-06 The United States Of America, As Represented By The Secretary Department Of Health And Human Services HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
MY207887A (en) * 2020-05-01 2025-03-26 Sinocelltech Ltd Method for improving immunogenicity of protein/peptide antigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100999548A (zh) * 2006-01-10 2007-07-18 海南天源康泽医药科技有限公司 白喉毒素突变体crm197及其制备方法
CN109963586A (zh) * 2016-07-21 2019-07-02 维克芙奥私人有限公司 作为抗疟疾疫苗的生物融合蛋白
CN108159408A (zh) * 2017-12-29 2018-06-15 云南沃森生物技术股份有限公司 一种多价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SHUN HU 等: "Conjugation of the CRM197-inulin conjugate significantly increases the immunogenicity of Mycobacterium tuberculosis CFP10-TB10.4 fusion protein", BIOORG MED CHEM, vol. 25, no. 21, 19 September 2017 (2017-09-19), pages 5968 - 5974 *
SHUXIONG CHEN等: "Design of Bacterial Inclusion Bodies as Antigen Carrier Systems", ADVANCED BIOSYSTEMS, vol. 2, no. 11, 4 September 2018 (2018-09-04), pages 1 - 13, XP072785974, DOI: 10.1002/adbi.201800118 *
李琼等: "流感病毒M2e与白喉毒素无毒突变体CRM197融合蛋白的抗原性和免疫原性分析", 病毒学报, vol. 33, no. 4, 26 July 2017 (2017-07-26), pages 483 - 493 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118191298A (zh) * 2022-12-14 2024-06-14 上海索昕生物科技有限公司 一种抗体免疫检测试剂及其制备方法和应用
CN116286682A (zh) * 2022-12-30 2023-06-23 中国农业科学院兰州兽医研究所 O型口蹄疫病毒多表位仿生纳米自组装病毒样颗粒及其制备方法和应用
CN116286682B (zh) * 2022-12-30 2026-04-07 中国农业科学院兰州兽医研究所 O型口蹄疫病毒多表位仿生纳米自组装病毒样颗粒及其制备方法和应用
CN117723749A (zh) * 2024-02-07 2024-03-19 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Also Published As

Publication number Publication date
EP4031170A4 (en) 2023-11-15
NL2023863B1 (en) 2021-05-25
US20220378894A1 (en) 2022-12-01
AU2020349589A1 (en) 2022-04-07
WO2021051153A9 (en) 2022-12-29
WO2021051153A1 (en) 2021-03-25
EP4031170A1 (en) 2022-07-27
JP2022549791A (ja) 2022-11-29

Similar Documents

Publication Publication Date Title
CN115175696A (zh) 包含白喉毒素交叉反应物质（crm）氨基酸序列的蛋白颗粒及其用途
US20210275664A1 (en) Prefusion coronavirus spike proteins and their use
Chen et al. Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy
CN102711794B (zh) 用于疫苗和诊断学的Dps融合蛋白
Freyn et al. Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice
JP2017521073A (ja) インフルエンザウイルスワクチンおよびその使用
Abdel-Aal et al. Structure–activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates
JP2021519597A (ja) 抗原性呼吸器合胞体ウイルスポリペプチド
Savard et al. Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles
ES2891973T3 (es) Partículas de polímero y usos de las mismas
US11078491B2 (en) Vaccines against Zika virus based on Zika structure proteins
US11179460B2 (en) Virus-like particles comprising zika antigen
NZ740816A (en) Compositions against cat allergy
US20240228549A1 (en) Prefusion-stabilized lassa virus glycoprotein complex and its use
JP2025063151A (ja) 抗原性多量体呼吸器合胞体ウイルスポリペプチド
JP6541158B2 (ja) 粘膜ワクチン用アジュバント
Yin et al. Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis
TW201427687A (zh) 黏膜疫苗用佐劑
HK40081102A (en) Protein particles comprising a diphtheria toxin cross reacting material (crm) amino acid sequence and uses thereof
US20220370604A1 (en) Peptide vaccine for virus infection
Ahmadbeigi et al. Immunopotentiation of the engineered low-molecular-weight pilin targeting Pseudomonas aeruginosa: A combination of immunoinformatics investigation and active immunization
He et al. Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus
CN118176204A (zh) 截短的流感神经氨酸酶及其使用方法
Zhu et al. Protection against the H1N1 influenza virus using self-assembled nanoparticles formed by lumazine synthase and bearing the M2e peptide
CN111948387A (zh) 结核分枝杆菌抗原蛋白Rv1485在制备结核疫苗中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081102

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221011